Homologous recombination

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication

Retrieved on: 
Thursday, September 28, 2023
Homologous recombination, DNA, Travel, University, CSO, Overalls, Survival, Therapy, Cancer, Woman, Research, Immunotherapy, Death, HRP, Patient, Paper, Research institute, Pharmaceutical industry, Ovarian cancer, MD

“There is a rising tide of key research demonstrating the importance of targeting clonal neoantigens in preclinical and clinical studies by multiple investigators and Gradalis,” said John Nemunaitis, MD, CSO of Gradalis, and corresponding author on the paper.

Key Points: 
  • “There is a rising tide of key research demonstrating the importance of targeting clonal neoantigens in preclinical and clinical studies by multiple investigators and Gradalis,” said John Nemunaitis, MD, CSO of Gradalis, and corresponding author on the paper.
  • “There is a clear opportunity for Vigil to differentiate and address the unmet medical need in HRP ovarian cancer patients.
  • Vigil is designed to improve the immune system’s ability to produce effector cells that travel and bind to clonal neoantigen targets.
  • Results suggest that Vigil treatment in HRP positive ovarian cancer patients enhance immunotherapeutic proficiency that is mediated by the capacity for high clonal neoantigen targeting.

Eric Kmiec, Ph.D., Named Editor-in-Chief of Gene and Genome Editing

Retrieved on: 
Wednesday, September 6, 2023
Kmiec, DNA, CRISPR, Gene, Augusta University, Genetics, Stanford University, Medical college, Gene editing, Pathology, Cancer, Medical College of Georgia, Inherited disorders of trafficking, Research, Lung, Master of Science, Knowledge, FDA, Therapy, Molecular medicine, Environment, Homologous recombination, Antibiotics, Vaccine

Wilmington, Delaware, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eric Kmiec, Ph.D., executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute , has been selected as editor-in-chief of the scientific journal Gene and Genome Editing .

Key Points: 
  • Wilmington, Delaware, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eric Kmiec, Ph.D., executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute , has been selected as editor-in-chief of the scientific journal Gene and Genome Editing .
  • “We have a unique opportunity to fill a void in the field by focusing on clear messages about the foundational aspects of gene editing and accepting papers that cover groundbreaking gene editing discoveries.”
    “I am delighted with Eric’s appointment and the plans he has to take the journal in a new direction,” said Susanne Steiginga, MSc, executive publisher of Gene and Genome Editing.
  • He is widely recognized for his pioneering work in the fields of molecular medicine and gene editing.
  • Throughout his professional career, Kmiec has led research teams in developing gene editing technologies and genetic therapies for inherited disorders and cancer.

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Tuesday, September 5, 2023
Nobel Prize, CRISPR, Therapy, Genomics, Biotechnology, Gene editing, Cas9, Research, ERS, Collection, Health, NICE, Homologous recombination, Pharmaceutical industry

DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe'). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe').
  • This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.
  • ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

Retrieved on: 
Tuesday, September 5, 2023
Nobel Prize, CRISPR, Therapy, Genomics, Biotechnology, Gene editing, Cas9, Research, ERS, Collection, Health, NICE, Homologous recombination, Pharmaceutical industry

DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe'). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with AlgenScribe SAS ('AlgenScribe').
  • This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio.
  • ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.

Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D

Retrieved on: 
Thursday, August 31, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Homologous recombination, Graft-versus-host disease, CRISPR, DNA, Radiation, Obesity, Asthma, Accreditation, PD, Therapy, NASH, Diabetes, Chronic kidney disease, CDX, IBD, HER2, Syngenic, Gene editing, Pathology, SPF, Atopic dermatitis, Multimedia, SLE, CD3E, CCR8, Atherosclerosis, Medication, PDX, MS, Psoriasis, Fibrosis, Service provider, HKEX, AAALAC, Immune system, Mouse, Cytokine, PD-1, ESC, B cell, Pharmacology, Rheumatoid arthritis, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.
  • With the company’s expanding initiatives focused on antibody drug development, the company has officially established two business divisions, with one focusing on animal models and preclinical services, and the other focusing on the discovery and development of novel antibody-based drugs for out-licensing and partnerships.
  • View the full release here: https://www.businesswire.com/news/home/20230831376847/en/
    Biocytogen’s preclinical platforms include custom gene-editing services, generation of off-the-shelf humanized and/or immunodeficient animal and cell model products, and preclinical pharmacology services.
  • To better showcase these business lines, and to enhance the brand image of the company’s preclinical models and services, the company will integrate these major platforms under the “BioMice™” sub-brand.

Biocytogen Establishes Two Business Divisions To Distinguish Preclinical Models and Services (BioMice) from Antibody Drug R&D

Retrieved on: 
Thursday, August 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Homologous recombination, Graft-versus-host disease, CRISPR, DNA, Radiation, Obesity, Asthma, Accreditation, PD, Therapy, NASH, Diabetes, Chronic kidney disease, CDX, IBD, HER2, Syngenic, Gene editing, Pathology, SPF, Atopic dermatitis, Multimedia, SLE, CD3E, CCR8, Atherosclerosis, Medication, PDX, MS, Psoriasis, Fibrosis, Service provider, HKEX, AAALAC, Immune system, Mouse, Cytokine, PD-1, ESC, B cell, Pharmacology, Rheumatoid arthritis, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.
  • With the company’s expanding initiatives focused on antibody drug development, the company has officially established two business divisions, with one focusing on animal models and preclinical services, and the other focusing on the discovery and development of novel antibody-based drugs for out-licensing and partnerships.
  • View the full release here: https://www.businesswire.com/news/home/20230830517505/en/
    Biocytogen’s preclinical platforms include custom gene-editing services, generation of off-the-shelf humanized and/or immunodeficient animal and cell model products, and preclinical pharmacology services.
  • To better showcase these business lines, and to enhance the brand image of the company’s preclinical models and services, the company will integrate these major platforms under the “BioMice™” sub-brand.

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

Retrieved on: 
Monday, August 21, 2023
Theta, GSK, DNA, Therapy, Neoplasm, HRD, POLQ, Cancer, Research, MMEJ, DNA polymerase, Investigational New Drug, Patient, Homologous recombination, Medicine, HR, BRCA, FDA, PARP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, DNA repair, Pharmaceutical industry, IND

We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.

Key Points: 
  • We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.
  • GSK101 is a potential first-in-class small molecule inhibitor of the helicase domain of DNA Polymerase Theta (Pol Theta).
  • The Pol Theta enzyme facilitates DNA repair through microhomology-mediated end joining (MMEJ), an enzymatic function that enables reversion of BRCA mutations.
  • GSK will lead clinical development for the Pol Theta program pursuant to its global, exclusive license to develop and commercialize the Pol Theta Helicase Inhibitor DC (GSK Pol Theta License).

DNA Repair Discoveries Hold Promise for New Approaches to Cancer Treatment

Retrieved on: 
Wednesday, August 16, 2023
Memorial Sloan Kettering Cancer Center, DNA, Radiation, WCM, Nature, DNA repair, NYU Langone Health, BRCA1, Microscopy, Cancer, MSKCC, Breast, Mutation, Cell, Doctor of Philosophy, Whole genome sequencing, National Cancer Institute, Protein, Chromosome, MD, Patient, WGS, Weill Cornell Medicine, Biology, Anurag Agrawal (medical scientist), BRCA2, BRCA, NCI, Homologous recombination, Vaccine, Microscope

In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.

Key Points: 
  • In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.
  • Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair.
  • For this reason, identifying patients with "HR-deficient" cancers has become a priority in the field, in part because such cancer cells are vulnerable to targeted therapies that break their DNA.
  • This work was supported by the Starr Cancer Consortium Award I11-005, National Cancer Institute (NCI) 1P50CA247749, and the Burroughs Wellcome Fund Career Award for Medical Scientists.

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Wednesday, August 9, 2023
Amgen, DNA, ZymoGenetics, AACR, Drug development, Therapy, DDR, Neoplasm, Uterine serous carcinoma, Paclitaxel, American Association for Cancer Research, Coronavirus Scientific Advisory Board, Woman, Outer ring road, Medication, Cyclin E1, Biomarker, Bayer, USC, Carboplatin, Carcinoma, MD Anderson Cancer Center, ASCO, Development, State Administrative Expenses, American Society of Clinical Oncology, Patient, Homologous recombination, SAN, University, Administration, Annual general meeting, Cancer, Clinical Ovarian Cancer & Other Gynecologic Malignancies, R, Research, Ovarian cancer, Society, ORR, Safety, Pharmaceutical industry, Cryptocurrency, Cyclin

NEW YORK and SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • Azenosertib plus chemotherapy combinations also demonstrated positive results in women facing heavily pretreated ovarian cancer.
  • Presented positive azenosertib + chemotherapy combination data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Zentalis is preparing for a Phase 3 trial of azenosertib using intermittent dosing in combination with chemotherapy in Cyclin E1+ platinum-sensitive ovarian cancer.
  • Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million.